Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by McGuire Investment Group LLC


McGuire Investment Group LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating ) by 2.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,473 shares of the company’s stock after purchasing an additional 1,386 shares during the period. Medpace makes up 1.9% of McGuire Investment Group LLC’s portfolio, making the stock its 21st biggest position. McGuire Investment Group LLC’s holdings in Medpace were worth $10,220,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Yarbrough Capital LLC boosted its holdings in Medpace by 80.7% in the first quarter. Yarbrough Capital LLC now owns 4,472 shares of the company’s stock valued at $732,000 after purchasing an additional 1,997 shares in the last quarter. Cim LLC boosted its holdings in Medpace by 2.8% in the first quarter. Cim LLC now owns 2,570 shares of the company’s stock valued at $409,000 after buying an additional 69 shares in the last quarter. Front Row Advisors LLC boosted its stake in Medpace by 3.9% in the 4th quarter. Front Row Advisors LLC now owns 10,809 shares of the company’s stock valued at $2,352,000 after acquiring an additional 409 shares in the last quarter. Green Square Capital Advisors LLC purchased a new position in Medpace during the 4th quarter valued at $218,000. Finally, Castleark Management LLC purchased a new position in Medpace during the 4th quarter valued at $9,694,000. 79.70% of the shares are owned by institutional investors and hedge funds.

Shares of Medpace stock opened at $156.70 on Wednesday. The firm’s 50-day moving average is $140.63 and its 200-day moving average is $159.32. Medpace Holdings, Inc. has a 1-year low of $126.94 and a 1-year high of $231.00. The company has a market cap of $5.27 billion, a P/E ratio of 29.24 and a beta of 1.43.

Medpace (NASDAQ:MEDP – Get Rating ) last posted its quarterly earnings results on Monday, April 25th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.43. Medpace had a net margin of 16.47% and a return on equity of 24.17%. The company had revenue of $330.90 million for the quarter, compared to the consensus estimate of $327.09 million. During the same period last year, the firm posted $1.17 EPS. The company’s revenue for the quarter was up 27.3% on a year-over-year basis. As a group, stock analysts expect Medpace Holdings, Inc. to post 5.87 EPS for the current year.

MEDP has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Medpace in a research note on Thursday, March 31st. They assign a “buy” rating to the stock. Guggenheim initiated coverage on shares of Medpace in a research note on Monday, May 23rd. They assign a “neutral” rating to the stock. Finally, Robert W. Baird boosted their price objective on shares of Medpace from $160.00 to $175.00 in a research note on Thursday, March 17th.

About Medpace (Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe and Asia. It offers a range of services supporting the clinical development process from phase I to phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology and medical industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, new drug submissions for pharmacovigilance, and post-marketing clinical support services.

Selected articles

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)



Get Medpace Daily news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.